Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$144.72
pos +0.00
+0.00%
Today's Range: 141.14 - 144.97 | AMGN Avg Daily Volume: 3,755,600
Last Update: 02/12/16 - 4:00 PM EST
Volume: 0
YTD Performance: -10.85%
Open: $0.00
Previous Close: $141.46
52 Week Range: $130.09 - $181.81
Oustanding Shares: 754,327,866
Market Cap: 106,707,219,924
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 2 2 1 1
Hold 9 8 9 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.30 2.25 2.36 2.31
Latest Dividend: 1.00
Latest Dividend Yield: 2.83%
Dividend Ex-Date: 02/11/16
Price Earnings Ratio: 13.63
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
13.63 15.60 26.86
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.15% -5.52% 71.17%
GROWTH 12 Mo 3 Yr CAGR
Revenue 7.40 0.25 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.63 0.18
Earnings for AMGN:
EBITDA 8.52B
Revenue 21.66B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $2.54 $2.72 $10.75 $11.79
Number of Analysts 10 8 11 8
High Estimate $2.76 $2.83 $10.85 $12.50
Low Estimate $2.42 $2.62 $10.63 $11.38
Prior Year $2.48 $2.57 $10.38 $10.75
Growth Rate (Year over Year) 2.46% 5.93% 3.55% 9.72%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
The market looks like it is expecting a significant domestic contraction in 2016, but I don't see it.
I am using the downturn to continue to build up positions in value stocks.
They offer impressive free cash flow, great balance sheets, evolving pipelines and nice dividend yields.

Stocks Continue to Sink Real Money Pro($)

The market's major indices are getting worse as the morning progresses.
In a year's time, investors may look back and think this was a great entry point.
It appears that Amgen's share price erosion may continue given its performance in recent weeks. 

Intermediate Trade: Amgen Real Money Pro($)

AMGN's charts show 3 bullish divergences; try a call spread to take advantage.
Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.
The year has not started the way most pundits and prognosticators had envisioned.
Each of these small-caps delivered good news recently, only to have their stocks decline.

Columnist Conversations

Judge Smails embarrassed me into writing it!
Some pretty obvious selling in the FATMAN names vs the Nasdaq futures post regular session open. FATM...
You can see the time/price support on the daily chart of SPX below. It also shows you the next major decision ...
$185.80 Exhausted and a long weekend. Column up shortly Sold some IWM as well.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.